Biolidics Full Year 2023 Earnings: S$0.004 loss per share (vs S$0.033 loss in FY 2022)

Biolidics (Catalist:8YY) Full Year 2023 Results

Key Financial Results

• Revenue: S$1.46m (down 43% from FY 2022).

• Net loss: S$2.49m (loss narrowed by 74% from FY 2022).

• S$0.004 loss per share (improved from S$0.033 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Biolidics' share price is broadly unchanged from a week ago.

Risk Analysis

You should learn about the 6 warning signs we've spotted with Biolidics (including 4 which make us uncomfortable).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.